Victoria Murrain, DO, has been promoted from interim to permanent deputy dean for diversity and inclusion at the University of Arizona College of Medicine – Tucson.

Pharmacogenetics expert, Jason Hansen Karnes, PharmD, PhD, BCPS, FAHA, has been named director of scientific programs for the All of Us Research Program team at the University of Arizona and Banner Health.

A research team led by Jared Churko, PhD, director of the University of Arizona iPSC Core in the UA Sarver Heart Center, used a transcriptomic approach — studying what genes are expressed — to identify gene signatures of cell subpopulations identified as atrial-like or ventricular-like. This understanding could lead to regenerative therapy discoveries for the millions of people living with damaged heart muscle caused by heart attacks or other chronic heart conditions.

University of Arizona scientists hope they have made progress toward a next-generation drug that may slow tumor growth and boost radiation’s effectiveness in patients with the deadly brain cancer.

Michael Kruer, MD, receives the first federally funded grant to research genetic causes of condition that affects 1 in 250 children.

Individuals with a particular genetic factor may be more resistant to plaque build-up and have a reduced risk for coronary artery disease.

A $2 million grant from the U.S. Department of Defense will support research on 3D-printed scaffolds that support the repair of devastating bone injuries.

In this new role, Dr. Mathias will oversee the clinical operations for all Banner – University Medicine family medicine clinics and clinical service lines.

Its ample sun puts residents at risk for melanoma, but Arizona is also home to experimental treatments through early-phase clinical trials at the University of Arizona Cancer Center.

Roberta Diaz Brinton, PhD, inaugural director of the Center for Innovation in Brain Science at the University of Arizona Health Sciences, is one of six international researchers awarded funding through the Alzheimer’s Association's Part the Cloud program to support early phase human trials of potential therapies to save brain cells.